EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Industry Insights: Bioconjugate innovation gains momentum across partnerships and pivotal trials

Lauren Coyle

Bioconjugate Insights · 19.03.2026 · 1 (1) · 49–66

DOI: 10.18609/bci.2026.008 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioconjugate Insights, online erschienen am 19.03.2026. Verfasst von Lauren Coyle. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

February saw a sustained pace of partnering and portfolio reshaping across the bioconjugate space, alongside multiple late-stage clinical and regulatory catalysts. On the dealmaking front, Chugai exercised its option to license Araris’ multi-payload linker-payload platform, while Wave regained full rights to its GalNAc-conjugated RNA-editing therapy from GSK and signaled plans to accelerate US FDA engagement. Collaboration activity also broadened beyond classic ADCs with HealZen initiating a cross-border partnership in degrader-antibody conjugates, StarkAge teaming with Gustave Roussy to support senolytics ADC development, and Rakuten Medical signing LOTTE Biologics for the manufacturing of antibody-dye photoimmunotherapy conjugates. Multiple platform and asset licenses underscored continued demand for differentiated formats, including B7-H3 ADC and bispecific/dual-payload ADC agreements with MediLink-Roche and Biocytogen-Acepodia, and proximity-guided multispecific work with InduPro-Lilly. Regulators advanced several programs, including Japan supplement NDA submissions for DATROWAY and PADVEC plus pembrolizumab, and China approval of ENHERTU in second-line HER2-positive gastric/gastroesophageal junction adenocarcinoma cancer. Clinically, first-patient dosing milestones spanned HER2, CD37, PD-L1, CDH17, and PSMA-targeted conjugates, while OPUS-3 initiated evaluation of VAX-31 in previously vaccinated adults. Market activity included Sutro’s $110M financing and Intensity’s reverse split, reflecting continued capital management amid ongoing development.

Zitieren

APA

Coyle, L. (2026). Industry Insights: Bioconjugate innovation gains momentum across partnerships and pivotal trials. Bioconjugate Insights, 1(1), 49–66. https://doi.org/10.18609/bci.2026.008

Vancouver

Coyle L. Industry Insights: Bioconjugate innovation gains momentum across partnerships and pivotal trials. Bioconjugate Insights. 2026;1(1):49–66. doi:10.18609/bci.2026.008

BibTeX
@article{Coyle2026,
  author = {Coyle, Lauren},
  title = {Industry Insights: Bioconjugate innovation gains momentum across partnerships and pivotal trials},
  journal = {Bioconjugate Insights},
  year = {2026},
  volume = {1},
  number = {1},
  pages = {49–66},
  doi = {10.18609/bci.2026.008}
}
Kostenlos starten →